An approach using engineered small extracellular vesicles from NK cells to DR5 could be a promising strategy for solid tumors.

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and ...

Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...

Scientists from the University of Pennsylvania have developed an innovative cancer treatment using small extracellular ...

The DR5 death receptor appears to have evolved ... Xu and his team used extracellular vesicles to target DR5 because these nano-sized capsules—about a million times smaller than a T cell ...

The experimental approach, which uses tiny capsules called small extracellular vesicles (sEVs ... to target a cell-surface receptor called DR5 (death receptor 5) that many tumor cells have.

Joseph Arboleda-Velasquez of Harvard Medical School praised the results. “Ye’s group has now provided compelling evidence showing increased binding affinity of ApoE3 Christchurch for tau and its ...

The peptide Palmitoyl-GHK (Pal-GHK) has garnered considerable attention in the scientific community due to its structural attributes and potential functional roles in biological research and cellular ...

Researchers at Penn Medicine created an innovative cancer treatment using nano-sized capsules that can target and trigger cancer cell self-destruction.

Innovative designs of GPCRs with enhanced signaling and stability offer new insights for drug discovery and synthetic biology ...